Abstract: An estimated 130 million people worldwide are chronically infected with hepatitis C virus (HCV) making it a leading cause of liver disease worldwide. Because the currently available therapy of pegylated interferon-alpha and ribavirin is only effective in a subset of patients, the development of new HCV antivirals is a healthcare imperative. This review discusses the experimental models available for HCV antiviral drug research, recent advances in HCV antiviral drug development, as well as active research being pursued to facilitate development of new HCV-specific therapeutics. Although HCV infection is usually asymptomatic and 10-30% of infected individuals successfully clear the infection [2, 145] , ~70% of infections persist with the risk of progressive liver complications, such as fibrosis, cirrhosis, steatosis, insulin resistance, and/or hepatocellular carcinoma (HCC) [4,5,43,71, 111, 133, 148,149] , which can ultimately necessitate liver transplantation if HCV infection is not successfully treated (Fig. 1 ).
Flaviviridae family of enveloped positive-strand RNA viruses, is a leading cause of liver disease worldwide.
Although HCV infection is usually asymptomatic and 10-30% of infected individuals successfully clear the infection [2, 145] , ~70% of infections persist with the risk of progressive liver complications, such as fibrosis, cirrhosis, steatosis, insulin resistance, and/or hepatocellular carcinoma (HCC) [4, 5, 43, 71, 111, 133, 148, 149] , which can ultimately necessitate liver transplantation if HCV infection is not successfully treated (Fig. 1 ).
To date, combination pegylated interferon-alpha (pIFN-α) and ribavirin [52] is the licensed standard of care (SOC) treatment for HCV; however, several limitations restrict its use and efficacy. First, because viral, host, and environmental factors significantly affect the success of SOC treatment (reviewed in [162] ), numerous contraindications limit the number of patients eligible for therapy. Of those who are treated, sustained virological response (SVR) is only achieved in ~80% of individuals infected with genotypes 2 or 3
and 40%-50% of individuals infected with genotypes 1 or 4 [3] . In addition, therapy itself has a spectrum of toxic side effects and complications, which severely 
HCV EXPERIMENTAL SYSTEMS AVAILABLE FOR ANTIVIRAL DRUG RESEARCH
Since it's discovery in 1989 as the causative agent on non-A non-B hepatitis [37] , the HCV lifecycle and host-virus interactions that determine infection outcome have been difficult to study because experimental HCV cell culture infection systems and suitable small animal models have not been readily available. Consequently, the development of preventive vaccines and anti-HCV therapeutics has been severely hampered.
Notably however, different model systems have now been developed and successfully used to study isolated aspects of the HCV lifecycle (Table 1 ) and three models in particular have significantly advanced our understanding of HCV and accelerated HCV antiviral development. These include the development of HCV replicons, HCV pseudotyped particles (HCVpp), and most recently infectious HCV cell culture systems, each of which is discussed in detail below.
HCV replicons
Shortly after the 1989 cloning of the HCV genome [37] , full length HCV RNA was synthesized and shown to be infectious in chimpanzees after intrahepatic Table 1 . HCV Experimental Models
Experimental Models HCV in vitro models ·HCV molecular clones [9, 66, 185] ·Expression systems [38, 112, 130, 146] ·Subgenomic and full length replicons [21, 22, 75, 84, 118, 167] ·Pseudotype particles (HCVpp) [10, 72] ·Infectious cell culture-propagated HCV (HCVcc) [113, 167, 191] HCV in vivo models ·Tree shrews, marmosets/tamarins [44, 83, 169, 175, 190] ·Chimpanzees [37, 94] ·Immunotolerized rat model [173] ·Transgenic mouse model [69, 86, 92, 107, 127, 136] ·Heterotopic liver graft mouse model [49, 76, 119] ·Hepatic xenorepopulation mouse model [19, 89, 90, 143] Surrogate systems ·GB virus B or bovine viral diarrhea virus [12, 28] inoculation [13, 70, 94, 176, 177, 179] providing insights into salient aspects of HCV infection and pathogenesis [93, 178] (reviewed in [29] and [100] ); however, these consensus clones were found to be replication defective in cell culture, limiting in vitro HCV model development. This changed in 1999, when Lohman et al overcame the in vitro HCV replication barrier by devising a genotype 1b HCV replicon system [118] based upon previous autonomous replication models of other flaviviruses [14, 88] . Specifically, selectable subgenomic HCV RNAs were engineered in which the region encoding the HCV structural genes, with or without NS2, was replaced by the selectable antibiotic resistant marker, neomycin phosphotransferase (Neo).
Upon transfection into mammalian cells, Neo is translated via the HCV internal ribosome entry site (IRES), while the viral nonstructural (NS) proteins
required to replicate the input template RNA are synthesized from the encephalomyocarditis virus (EMCV) IRES (Fig. 2) . Antibiotic-resistant cell clones, harboring autonomously replicating HCV replicon RNA can then be selectively expanded.
Although it was discovered that robust HCV replicon replication required numerous cell culture adaptive mutations [21, 98, 116, 117] which when cloned back into a full length construct resulted in an HCV genome incapable of producing infectious virus [8] or causing infection in chimpanzees following intrahepatic inoculation [30, 139] , HCV replicons have proven invaluable for the in vitro study of HCV replication and subgenomic replicons of several genotypes (e.g. 1a,
1b and 2a) as well as full-length replicons having been developed [21, 22, 75, 84, 167] . In addition to the identification of RNA elements and proteins involved in the viral replication process, HCV replicons have provided the means to characterize the viral replication complex at the biochemical and ultrastructural level with fluorescently-tagged viral proteins, such as a NS5A-GFP fusion, having allowed for visualization and tracking HCV replication complexes in living cells [155, 172] . Most important to anti-HCV drug discovery and the study of HCV drug resistance, numerous replicon constructs with exogenous reporters, such as luciferase, secreted alkaline phosphatase, chloramphenicol transferase, beta-lactamase, or beta-galactasidase have facilitated the development of reporter-based HCV replication screening assays [53, 67, 98, 129, 182, 183] .
HCV pseudotyped particles (HCVpp)
To allow for the study of HCV entry, researchers created infectious pseudoparticles incorporating the HCV E1-E2 glycoproteins on murine leukemia virus (MLV) or HIV-1 retroviral core particles [10, 72] . Although
HCVpp only resemble HCV at the level of surface glycoprotein expression, their ability to mimic HCV entry has helped dissect the HCV entry process identifying numerous cellular entry factors and neutralizing epitopes on the viral glycoproteins [63, 87, 166, 187] . With pseudotype particles of all six HCV genotypes now available encoding for various reporter proteins (e.g. GFP, β-galactosidase, or luciferase) the HCVpp system represents a focused tool for studying HCV entry across many HCV genotypes and thus will undoubtedly continue to facilitate the development of viral entry inhibitors, as illustrated by a 2009 report describing a luciferase-based HCVpp high throughput screening approach for the identification of HCV entry inhibitors [180] .
HCV cell culture infection systems
The ability to recapitulate the entire viral lifecycle in vitro was finally achieved in 2005 when several groups shown above each protein for HCV H77 strain; genotype 1a; GenBank accession number AF011752). Dark blue arrows denote cleavage sites by the endoplasmic reticulum signal peptidase, purple arrow indicates C-terminal processing of the core protein by signal peptide peptidase and black and red arrows indicate cleavages by the HCV NS2/3 and NS3/4a proteases, respectively. The structural proteins (blue) are located at the 5' end of the ORF, followed by p7 (aqua) and the non-structural (NS) proteins (green).
Descriptive titles and known activities for each viral protein are listed.
reported robust HCV infection and production of infectious progeny HCV (termed HCVcc) in Huh7 human hepatoma cell cultures using the HCV genotype 2a JFH-1 consensus genome cloned from a Japanese Fulminant Hepatitis patient or derivative thereof [85, 113, 167, 191] . These systems yield viral titers between 10 4 -10 6 infectious units/mL allowing infection to spread throughout a culture within days after inoculation at low multiplicities of infection (MOI) and the serial passage of virus without loss in infectivity. Importantly, HCVcc is infectious in chimpanzees and primary human hepatocytes transplanted into SCID-uPA mice, and virus recovered from these animals is infectious in vitro [65, 114] . . Unlike typical viral HTS assays that infect at a high MOI and are thus focused on a single cycle of virus replication, the assay described by Yu et al. to be detected over the course of several rounds of viral replication and spread [186] . [64, 122] and Boceprevir (BVR; SCH503034; Schering) [99, 153] ] and NS5B polymerase inhibitors (reviewed in [162] ). The In particular, we show here lipid droplets (LD), which are thought to be the site of HCV particle assembly, closely associated with the membranous web; however the spatial relationship of these two viral activities remains to be determined. GAG, glycosaminoglycan; LDLR, low density lipoprotein receptor; SR-B1, scavenger receptor class B member I, CLDN1, claudin-1;
OCLN, occludin; IRES, internal ribosome entry site; LD, lipid droplets. 
HCV entry
HCV infection begins with the binding of the viral particle to receptors on the host cell surface. Four cellular receptors have been shown to be necessary, but not sufficient for HCV entry, the tetraspanin protein CD81 [10, 72, 140, 174, 191] , the scavenger receptor class B member I (SR-B1) [10, 60, 82, 154, 188] , and the tight junction proteins CLDN1 [42] and OCLN [15, 115, 141] (Fig.   3 , Step 1). Following a multi-step binding event, the viral particle is taken up into the cell via clathrincoated mediated endocytosis [20, 123] (Fig. 3, Step 2). [26, 31, 105, 125] has permitted the in vitro discovery of a number of novel HCV entry inhibitors which may prove to be effective clinically.
For example, the compound Terfenadine has been shown to interfere with the HCV-E2-CD81 receptor interaction [68] . Likewise, serum amyloid A may similarly function by binding to SR-B1 preventing HCV-SR-B1 interactions [32, 102] . Post binding inhibition of HCV membrane fusion in vitro has been reported with the broad-spectrum antiviral compound, Arbidol [24, 25, 137] . More recently, post-binding inhibition was demonstrated both in vitro and in vivo in the chimeric mouse model using amphipathic DNA polymers, which are hypothesized to block viral entry at the level of virion internalization and/or fusion [121] . Notably, however, several entry inhibitors are already at the clinical trial phase including the human hepatitis C immune globulin Civacir (Nabi Biopharmacueticals) [39] and the SR-B1 inhibitor ITX5061 (iTherX Pharmaceuticals) [120] , both of which inhibit HCV entry at the level of virion-receptor interactions.
Viral protein synthesis and processing
The . As such, protease inhibitor development has progressed with two promising protease inhibitors currently in
Phase III clinical trials.
Viral replication
Once expressed, the viral proteins NS3 to NS5B, directed at least in part by NS4B [57] , assemble on and remodel cytoplasmic ER membranes to form viral RNA replication complexes, which have been termed the membranous web [54] (Fig. 3, Step 6-7). Within (Table 2) . Meanwhile, accumulating data continues to reveal that HCV RNA replication is a highly complex process, dependent on both viral and host proteins (reviewed in [23] ), all of which could potentially serve as antiviral targets. In fact, the viral hydrophilic phosphoprotein, NS5A is required for HCV RNA replication, most likely via association with host cell proteins [73] . , and the liver-specific microRNA miR-122 inhibitor LNA-antimiR/SPC3649 (Santaris Pharma) [81, 101] , but it is anticipated many more will follow.
Viral assembly and release
The details of HCV virion assembly, maturation and egress are the least understood, as they have only recently become amenable to systematic study with the development of the HCVcc infection system.
Nonetheless, based on other flavivirus systems [170] , encapsidated HCV virions are believed to become enveloped with E1/E2 bearing cellular membranes upon budding into the ER. Progeny virions are believed to then exit the cell via the secretory pathway, during which glycosylation of viral glycoproteins and association with cellular lipoproteins (e.g. very-low density lipoproteins (vLDL)) occurs. (Fig. 2 , Steps 8-9). As the viral proteins and viral-host interactions that mediate capsid assembly, envelopment, and virion maturation are elucidated a plethora of promising drug targets are being identified. In terms of viral targets, a screen to identify compounds that inhibit HCV core dimerization was recently reported [95] and other viral proteins, such as p7 [58] and NS2 [79, 80] , are also emerged as essential factors in viral assembly and release. In terms of cellular targets, host factors involved in lipoprotein secretion are prime candidates [144] and it has been shown that infectious
HCVcc particle egress is blocked by the vLDL secretion inhibitor naringenin found in grapefruit [131] .
One resulting in anti-HCV activity in vitro [158] . Celgosivir 
Cell culture infection with other HCV genotypes
Robust HCV infection in cell culture has only been achieved with genotype 2a derivative clones. While attempts to propagate the infectious genotype 1a H77
clone [184] and an infectious genotype 1b virus in cell culture [139] have resulted in detectable HCV levels, de novo virus production was low, limiting the utility of the systems. We do not fully understand the restriction that prevent efficient propagation other HCV genotypes in vitro, but studies have mapped the 3' end of the JFH-1 clone as sufficient to confer replication permissiveness to other HCV clones, therefore chimeric HCV genomes containing these necessary 3'
region of the JFH-1 clone recombined with the corresponding 5' regions from genotypes 1-6 have been developed [55, 56, 78, 138, 156] .
Physiological relevant hepatocyte cell cultures
In addition to expanding the repertoire of available infectious HCV clones, improvements in hepatocyte cell culture is required as well. To date, robust HCV infection has only been published in one continuous human hepatoma cell line, Huh7 [96, 113, 132, 150] . Studying HCV infection in Huh7 cells has certainly expanded our ability investigate the viral life cycle; however, Huh7 cells are transformed and only marginally mimic the state of hepatocytes in vivo [126, 160] , which limits our ability to elucidate how HCV interacts with and induces alterations in hepatocytes in vivo to produce clinically observed HCV-associated liver disease. To address this issue, novel two-dimensional [151] and three-dimensional [152] culture systems have been developed to coax Huh7 cells to up-regulate hepatocyte-specific transcripts, become Phase I and Phase II drug metabolism competent [36] , and exhibit more specific localization of tight junction, cell adhesion, and polarity markers [152] . While these systems may prove useful in understanding how HCV interacts with polarized cells or disrupts specific aspects of hepatocyte physiology, Huh7 cells by nature remain transformed. As such, primary liver cell cultures remain the most physiologically relevant in vitro model for the study of HCV, and numerous laboratories are trying to develop ways to adapt primary human hepatocytes for HCV research [6, 27, 192] .
One recent publication of note describes a human hepatocyte cell culture system permissible to infection with patient serum of HCV genotypes 1, 2, 3 and 4 mimicking the kinetics of HCV infection in humans and producing infectious virions that can infect naïve human hepatocytes [27] . More recently, HCV infection was established in micropatterned co-cultures (MPCCs) of primary human hepatocytes with supportive stroma [142] , which is relevant to antiviral screening because MPCCs can be readily 
HCV small animal model development
The most significant obstacle impeding the preclinical testing of new HCV therapeutics and development of vaccines is the lack of HCV small animal models (reviewed in [143] ). Efforts to develop small animal infection models have included trying to transmit HCV to tree shrews [175, 190] , marmosets/ tamarins [44, 83, 169] , and other primates [1] , but only the chimpanzee model of HCV infection, has proven efficacious [93, 178] . [34, 165] indicating that a species block at the level of HCV RNA replication can be overcome, but that additional blocks in post-replication steps involved in progeny virus production may exist [165] . In terms of HCV entry, Ploss et al., recently determined the species-specific determinants for HCVpp entry into mouse cells to be human CD81 and human occludin, as expression of these two human receptors in murine fibroblast cell lines resulted in permissiveness for HCVpp [141] .
Notably however, infectious HCVcc entry could not be demonstrated suggesting additional entry factors are required for HCVcc entry into mouse cells. Hence, although we have made advancements towards the development of an HCV-permissive mouse model, this goal has yet to be achieved.
CONCLUSIONS
The lack of targeted HCV-specific treatments to date has hindered the success of HCV treatment strategies. However, the HCV experimental models and HTS assays described in this review have already led to the discovery of numerous potential HCV therapeutics, and ongoing efforts to improve and expand upon these experimental models will continue to benefit the HCV antiviral drug development effort.
As such, new HCV therapeutics are on the horizon and promise a future in which effective HCV treatment may be achieved with a "cocktail" approach comprised of compounds that specifically target the virus and critical viral-host interactions.
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